Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 2,431 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $4.31, for a total transaction of $10,477.61. Following the transaction, the director now directly owns 66,432 shares of the company’s stock, valued at approximately $286,321.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Rosty Raykov also recently made the following trade(s):

• On Tuesday, October 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $4.94, for a total transaction of $12,009.14.

Fennec Pharmaceuticals Price Performance

Shares of FENC opened at $4.95 on Thursday. The stock has a market cap of $135.73 million, a PE ratio of 123.75 and a beta of 0.27. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02. Fennec Pharmaceuticals Inc has a fifty-two week low of $4.09 and a fifty-two week high of $11.92. The firm’s 50-day simple moving average is $4.89 and its two-hundred day simple moving average is $6.18.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $13.67 million. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a net margin of 5.59%. During the same quarter last year, the company posted ($0.21) EPS. Analysts anticipate that Fennec Pharmaceuticals Inc will post 0.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $14.00 price target (down previously from $16.00) on shares of Fennec Pharmaceuticals in a research report on Tuesday, August 13th. Craig Hallum reduced their price target on shares of Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright reduced their price target on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 22nd.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in Fennec Pharmaceuticals in the second quarter worth about $49,000. The Manufacturers Life Insurance Company purchased a new stake in Fennec Pharmaceuticals in the second quarter worth about $69,000. Rhumbline Advisers grew its holdings in Fennec Pharmaceuticals by 44.7% in the second quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock worth $178,000 after purchasing an additional 8,987 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Fennec Pharmaceuticals by 67.7% in the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock worth $364,000 after buying an additional 13,223 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Fennec Pharmaceuticals by 71,275.0% in the first quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock worth $381,000 after buying an additional 34,212 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.